Nkarta (NKTX)
(Real Time Quote from BATS)
$5.41 USD
+0.11 (2.08%)
Updated Jul 9, 2024 01:24 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NKTX 5.41 +0.11(2.08%)
Will NKTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTX
All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy
Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug
NKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks
Should You Buy Nkarta (NKTX) Ahead of Earnings?
Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know
Other News for NKTX
Stifel Nicolaus Reaffirms Their Buy Rating on Nkarta (NKTX)
Buy Rating Affirmed for Nkarta Amid Advancements in Autoimmune Disease Treatments
Buy Rating on Nkarta’s Stock: Promising NKX019 Clinical Studies and Comparative Advantages
Nkarta Advances Clinical Trials and Explores New Treatments
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications